Ocugen is trading 5% lower at $0.75 amid biotech sector pressure, with XBI down 2.08% during the session.
- No clear company-specific announcement explains the October 23 decline. Ocugen’s November 4 earnings announcement and European affiliate news predate this session.
- An October 23 report concerns a CEO share sale made October 9, not a new transaction today. Broader market weakness may also add pressure.